Bayer to Acquire KaNDy Therapeutics for Augmenting its Women’s Healthcare Portfolio
Shots: KaNDy to receive $425M upfront, ~$450M milestones until launch followed by additional commercial milestones. The transaction is expected to be completed in Sept’2020 The acquisition will add KaNDy’s menopause drug to Bayer’s portfolio. KaNDy has published results of its NT-814 in P-IIb study that… Read More »Bayer to Acquire KaNDy Therapeutics for Augmenting its Women’s Healthcare Portfolio
